Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE:
Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor
receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests. The
investigators' phase I study has shown that the drug's toxicity is manageable.
PURPOSE:
1. Studying how well Apatinib works in treating patients.
2. Finding the efficacy and safety of 500 mg or 750mg Apatinib.
3. Pharmacokinetics/Pharmacodynamics(PK/PD).
4. Exploring new outcome measures of antiangiogenic drugs.